Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors

• US 8,323,883 B1
• Filed: 10/12/2010
• Issued: 12/04/2012
• Est. Priority Date: 10/09/2009
• Status: Expired due to Fees

• Current Assignee: Cold Spring Harbor Laboratory
• Original Assignee: Cold Spring Harbor Laboratory
• Inventors: Sordella, Raffaella, Fenoglio, Silvia, Lindsted, Trine
• Primary Examiner(s): KEMMERER, ELIZABETH
• Application Number:
  US12/903,133
• Time in Patent Office: 784 Days
• Field of Search: None
• US Class Current: 435/4
• CPC Class Codes: G01N 2333/5412 IL-6
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57415 of breast
• CPC Class Codes: G01N 33/57423 of lung
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney
• CPC Class Codes: G01N 33/6869 Interleukin

Abstract

Cancer treatment with a combination of an Epidermal Growth Factor Receptor tyrosine kinase inhibitor and an Interleukin-6 inhibitor.

Claims

1. A method or assessing the likelihood that a subject with Epidermal Growth Factor Receptor kinase inhibitor-resistant cancer will benefit from therapy that increases sensitivity to a Epidermal Growth Factor Receptor kinase inhibitor, the method comprising:

(a) providing a cellular tissue sample of the subject;

wherein the sample comprises non-small cell lung carcinoma cells, breast cancer cells, or pancreatic cancer cells;

(b) determining whether the non-small cell lung carcinoma cells, breast cancer cells, or pancreatic cancer cells carry an oncogenic mutation in the Epidermal Growth Factor Receptor that is associated with Epidermal Growth Factor Receptor tyrosine kinase inhibitor resistance, and

(c) determining the level in the sample of at least one marker selected from the group consisting of IL-6 mRNA level and IL-6 protein level, wherein presence of the oncogenic mutation and an elevated level of at least one marker in the sample as relative to a control indicates that the subject is likely to benefit from the therapy that increases sensitivity to a Epidermal Growth Factor Receptor kinase inhibitor.

2. The method of claim 1, wherein the EGFR-tyrosine kinase inhibitor is erlotinib or gefitinib.

3. The method of claim 1, wherein the oncogenic mutation in the Epidermal Growth Factor Receptor that is associated with Epidermal Growth Factor Receptor tyrosine kinase inhibitor resistance is selected from the group consisting of the variant III mutation, a KRAS mutation, a combination of L858R and T790M, and a combination of delE746-A750 and T790M.

4. The method of claim 3, wherein the oncogenic mutation in the Epidermal Growth Factor Receptor that is associated with Epidermal Growth Factor Receptor tyrosine kinase inhibitor resistance is variant III mutation.

5. The method of claim 3, wherein the oncogenic mutation in the Epidermal Growth Factor Receptor that is associated with Epidermal Growth Factor Receptor tyrosine kinase inhibitor resistance is a KRAS mutation.

6. The method of claim 3, wherein the oncogenic mutation in the Epidermal Growth Factor Receptor that is associated with Epidermal Growth Factor Receptor tyrosine kinase inhibitor resistance is a combination of L858R and T790M.

7. The method of claim 3, wherein the oncogenic mutation in the Epidermal Growth Factor Receptor that is associated with Epidermal Growth Factor Receptor tyrosine kinase inhibitor resistance is a combination of delE746-A750 and T790M.